대한암한의학회지 (Journal of Korean Traditional Oncology)

  • 제21권2호
  • /
  • Pages.37-50
  • /
  • 2016
  • /
  • 1975-244X(pISSN)
  • /
  • 2765-4850(eISSN)
대한암한의학회 (Korean Association of Traditional Oncology)
권호 표지
DOI QR코드

DOI QR Code

난소암 치료에 대한 한의 임상 가이드라인

Clinical Practice Guideline for Korean Medicine for Ovarian Cancer

  • 김경순 (대구한의대학교 한의과대학 간계내과학교실) ;
  • 최홍식 (대구한의대학교 한의과대학 간계내과학교실) ;
  • 김승모 (대구한의대학교 한의과대학 간계내과학교실) ;
  • 유화승 (대전대학교 둔산한방병원 동서암센터)
  • Kim, Kyung-Soon (Department of Korean Internal Medicine of Hepatology, Daegu Haany University) ;
  • Choi, Hong-Sik (Department of Korean Internal Medicine of Hepatology, Daegu Haany University) ;
  • Kim, Seung-Mo (Department of Korean Internal Medicine of Hepatology, Daegu Haany University) ;
  • Yoo, Hwa-Seung (East West Cancer Center, Dunsan Korean Medicine Hospital of Daejeon University)
  • 투고 : 2016.11.18
  • 심사 : 2016.12.05
  • 발행 : 2016.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Ovarian cancer is the tenth most common cancer in Korean female, and the third most common cancer of female reproductive organ after breast cancer and uterine cervical cancer. In spite of develop of conventional treatment, high modality of ovarian cancer comes from difficulty of an early diagnosis. Recent studies revealed that combining conventional and integrative medical treatment can reduce the adverse effect of surgical operation, chemotherapy and radiotherapy. Also it can improve survival rate, quality of life. However there isn't still a systemic clinical protocol for ovarian cancer in Korean medicine. This study will be helpful to establish clinical practice guidelines of Korean Medicine for ovarian cancer. And further studies on integrative ovarian cancer treatment are needed to build the clinical practice guidelines of ovarian cancer.

키워드

참고문헌

  1. 국가암정보센터. http://www.cancer.go.kr/mbs/cancer/subview.jsp?id=cancer_040101000000.
  2. Chereau E, Ballester M, Rouzier R, Coutant C, Darai E. Advanced ovarian cancer: criteria of resectability. Bulletin du cancer. 2009;96(12):1189-97.
  3. Baiocchi G, Cestari LA, Macedo MP, Oliveira RA, Fukazawa EM, Faloppa CC, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. Journal of surgical oncology. 2011;104(3):250-4. https://doi.org/10.1002/jso.21940
  4. Picaud L, Thibault B, Mery E, Ouali M, Martinez A, Delord JP, et al. Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. Journal of ovarian research. 2014;7:40. https://doi.org/10.1186/1757-2215-7-40
  5. Menzies D. Postoperative adhesions: their treatment and relevance in clinical practice. Annals of the Royal College of Surgeons of England. 1993;75(3):147-53.
  6. Ushijima K. Treatment for recurrent ovarian cancer-at first relapse. Journal of oncology. 2010;2010:497429.
  7. Kim KD, Kang SB, Chung HH, Kim JW, Park NH, Song YS, et al. Clinical characteristics of ovarian cancer patients who underwent enterostomy. Korean journal of obstetrics and gynecology. 2008;51(7):732-7.
  8. Choi JH, Suh MJ, Park DC. The correlation of clusterin binding affinity to chemotherapeutic agents with chemoresistance in ovarian cancer cells. Korean journal of obstetrics and gynecology. 2008;51(7):738-43.
  9. 난소암 진료권고안(ver. 3.0). 부인종양학회. 2015. http://www.sgo.or.kr/community/pdf/guide_01_2016_03.pdf.
  10. 林洪生. 惡性腫瘤中醫診療指南. 北京, 人民衛生出版社, p. 448-70, 2014.
  11. Walker JL, Powell CB, Chen LM, Carter J, Jump VL, Parker LP, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108-20. https://doi.org/10.1002/cncr.29321
  12. Falconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015; 107(2):dju410. https://doi.org/10.1093/jnci/dju410
  13. Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121(1):14-24. https://doi.org/10.1097/AOG.0b013e3182783c2f
  14. Kim SC. Recent advances in ovarian cancer treatment. J Korean Med. 2016;59(3):164-6.
  15. Chang SJ. Surgical management of ovarian cancer. J Korean Med Assoc 2016;59:167-74. https://doi.org/10.5124/jkma.2016.59.3.167
  16. Lim MC, Park SY. Chemotherapy for ovarian cancer. J Korean Med Assoc 2016;59:175-9. https://doi.org/10.5124/jkma.2016.59.3.175
  17. Kim JW. Targeted therapy and immunotherapy in ovarian cancer. J Korean Med Assoc. 2016;59:180-8. https://doi.org/10.5124/jkma.2016.59.3.180
  18. Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. Oct 2009;19(7):1199-204. https://doi.org/10.1111/IGC.0b013e31819d82c3
  19. Kajiyama H, Shibata K, Mizuno M, et al. Fertility-sparing surgery in young women with mucinous adenocarcinoma of the ovary. Gynecologic oncology. 2011;122(2):334-8. https://doi.org/10.1016/j.ygyno.2011.04.016
  20. Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, Raspagliesi F. Fertility sparing surgery in early stage epithelial ovarian cancer. Journal of gynecologic oncology. Oct 2014;25(4):320-7. https://doi.org/10.3802/jgo.2014.25.4.320
  21. Oshita T, Itamochi H, Nishimura R, et al. Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. International journal of clinical oncology. 2013;18(6):1107-13. https://doi.org/10.1007/s10147-012-0483-8
  22. Svolgaard O, Lidegaard O, Nielsen MLS, Nedergaard L, Mosgaard BJ, Lidang M, et al. Lymphadenectomy in surgical stage I epithelial ovarian cancer. Acta obstetricia et gynecologica Scandinavica. 2014;93(3):256-60. https://doi.org/10.1111/aogs.12322
  23. Chi DS, Eisenhauer EL, Zivanovic O, Sonodaa Y, Abu-Rustuma NR, Levinea DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009; 114(1):26-31. https://doi.org/10.1016/j.ygyno.2009.03.018
  24. Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, et al. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal of surgical oncology. 2013;107(2):195-200. https://doi.org/10.1002/jso.23171
  25. Fago-Olsen CL, Ottesen B, Kehlet H, Antonsena SL, Christensenc IJ, Markauskasd A, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecologic oncology. 2014;132(2):292-8. https://doi.org/10.1016/j.ygyno.2013.11.035
  26. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer(CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249-57. https://doi.org/10.1016/S0140-6736(14)62223-6
  27. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson J, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53. https://doi.org/10.1056/NEJMoa0908806
  28. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki T, et al. Dosedense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331-8. https://doi.org/10.1016/S0140-6736(09)61157-0
  29. Pignata S, Scambia G, Katsaros D, Isonishi S, Jobo T, Aoki D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. The Lancet. Oncology. 2014;15(4):396-405. https://doi.org/10.1016/S1470-2045(14)70049-X
  30. van der Burg ME, Onstenk W, Boere IA, Look M, Ottevanger PB, de Gooyer D, et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. European journal of cancer. 2014;50(15):2592-601. https://doi.org/10.1016/j.ejca.2014.07.015
  31. Walker JL, Armstrong DK, Huang HQ, Jeffrey F, Kenneth W, Robert BA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27-32. https://doi.org/10.1016/j.ygyno.2005.11.013
  32. Mobus V, Wandt H, Frickhofen N, Bengala C, Kim C, Rainer K, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. J Clin Oncol. 2007;25(27):4187-93. https://doi.org/10.1200/JCO.2006.09.7527
  33. Aghajanian C, Blank SV, Goff BA. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2039-45. https://doi.org/10.1200/JCO.2012.42.0505
  34. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1302-8. https://doi.org/10.1200/JCO.2013.51.4489
  35. 박재갑, 방영주, 하성환. 종양학. 서울, 일조각, p. 561-80, 2012.